Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: Evidence for association with atherogenic lipid profile

Clinical and Experimental Medicine

Volumn 9, Issue 3, 2009, Pages 243-248

  Zanetti, Michela ^a   Bosutti, Alessandra ^a   Ferreira, Clara ^a   Vinci, Pierandrea ^a   Biolo, Gianni ^a   Fonda, Maurizio ^b   Valente, Matteo ^b   Cattin, Luigi ^b   Guarnieri, Gianfranco ^a   Barazzoni, Rocco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

Author keywords

Atherosclerosis; HDL cholesterol; Metabolic syndrome; Pentraxin 3

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; TRIACYLGLYCEROL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPID; SERUM AMYLOID P;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; ECHOGRAPHY; MIDDLE AGED; PATHOLOGY;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SERUM AMYLOID P-COMPONENT;

EID: 70349786070     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-009-0039-z     Document Type: Article

References (30)

1. KK Koh SH Han MJ Quon 2005 Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions J Am Coll Cardiol 46 1978 1985 16325028 10.1016/j.jacc.2005.06.082 1:CAS:528:DC%2BD2MXht1OntbfE (Pubitemid 41713578)
2. S Malik ND Wong SS Franklin, et al. 2004 Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults Circulation 110 1245 1250 15326067 10.1161/01.CIR.0000140677.20606.0E (Pubitemid 39202340)
3. HM Lakka DE Laaksonen TA Lakka, et al. 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2709 2716 12460094 10.1001/jama.288.21.2709 (Pubitemid 35403784)
4. AM McNeill WD Rosamond CJ Girman, et al. 2004 Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study) Am J Cardiol 94 1249 1254 15541239 10.1016/j.amjcard.2004.07.107 (Pubitemid 39469942)
5. SM Grundy 2006 Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance Clin Cornerstone 8 S21 S27 16903166 10.1016/S1098-3597(06)80005-0 (Pubitemid 44283558)
6. A Mantovani C Garlanda B Bottazzi, et al. 2006 The long pentraxin PTX3 in vascular pathology Vascul Pharmacol 45 326 330 17023219 10.1016/j.vph.2006.08. 011 1:CAS:528:DC%2BD28Xht1CqtbfM (Pubitemid 44765293)
7. E Napoleone A di Santo G Peri, et al. 2004 The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation J Leukoc Biol 76 203 209 15226367 10.1189/jlb.1003528 1:CAS:528:DC%2BD2cXlsVOisLk%3D (Pubitemid 38857188)
8. E Napoleone A Di Santo A Bastone, et al. 2002 Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation Arterioscler Thromb Vasc Biol 22 782 787 12006390 10.1161/01.ATV.0000012282.39306.64 1:CAS:528: DC%2BD38XjslGmtbg%3D (Pubitemid 34517789)
9. M Klouche G Peri C Knabbe, et al. 2004 Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells Atherosclerosis 175 221 228 15262177 10.1016/j.atherosclerosis.2004.03.020 1:CAS:528:DC%2BD2cXlsl2gt78%3D (Pubitemid 38942901)
10. F Breviario EM d'Aniello J Golay, et al. 1992 Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component J Biol Chem 267 22190 22197 1429570 1:CAS:528:DyaK3sXksVahtbk%3D
11. MS Rolph S Zimmer B Bottazzi, et al. 2002 Production of the long pentraxin PTX3 in advanced atherosclerotic plaques Arterioscler Thromb Vasc Biol 22 e10 e14 12006411 10.1161/01.ATV.0000015595.95497.2F
12. N Kotooka T Inoue D Fujimatsu, et al. 2008 Pentraxin 3 is a novel marker for stent-induced inflammation and neointimal thickening Atherosclerosis 197 368 374 17640648 10.1016/j.atherosclerosis.2007.05.031 1:CAS:528: DC%2BD1cXisVSlsLk%3D (Pubitemid 351273259)
13. G Peri M Introna D Corradi, et al. 2000 PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans Circulation 102 636 641 10931803 1:CAS:528:DC%2BD3cXlvFyms7c%3D
14. R Latini AP Maggioni G Peri, et al. 2004 Lipid Assessment Trial Italian Network (LATIN) investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction Circulation 110 2349 2354 15477419 10.1161/01.CIR.0000145167.30987.2E 1:CAS:528:DC%2BD2cXosVSlsLY%3D (Pubitemid 39407338)
15. M Boehme F Kaehne A Kuehne, et al. 2007 Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease Nephrol Dial Transplant 22 2224 2229 17496115 10.1093/ndt/gfl747 1:CAS:528: DC%2BD2sXos1yltLw%3D (Pubitemid 47244700)
16. G Malaponte M Libra Y Bevelacqua, et al. 2007 Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines Int J Mol Med 20 471 481 17786277 1:CAS:528:DC%2BD2sXht1Srt7vP
17. S Suzuki Y Takeishi T Niizeki, et al. 2008 Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure Am Heart J 155 75 81 18082493 10.1016/j.ahj.2007.08.013 1:CAS:528:DC%2BD2sXhsVenurnI (Pubitemid 350234768)
18. National Institutes of Health Third Report of the National Cholesterol Education (2001) Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary, Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute (NIH publ. no. 01-3670)
19. DJ Hampel J Pratschke G May, et al. 2006 Living kidney donation: anemia and inflammation in the early postoperative period Transplant Proc 38 661 663 16647436 10.1016/j.transproceed.2006.01.066 1:STN:280:DC%2BD283ktFGgtA%3D%3D (Pubitemid 44389508)
20. WE Boden 2000 High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial Am J Cardiol 86 19L 22L 11374850 10.1016/S0002-9149(00)01464-8 1:CAS:528:DC%2BD3MXksVersg%3D%3D
21. Y Hong X Jin J Mo, et al. 2007 Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the atherosclerosis risk in communities study J Intern Med 262 113 122 17598819 10.1111/j.1365-2796.2007.01781.x 1:STN:280: DC%2BD2szot1ChtA%3D%3D (Pubitemid 47000624)
22. K Wallenfeldt J Hulthe B Fagerberg 2005 The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow up J Intern Med 258 28 37 15953130 10.1111/j.1365-2796.2005.01511.x 1:STN:280: DC%2BD2Mzgs1ejtQ%3D%3D (Pubitemid 40904930)
23. Alberti A, Gilardini L, Zulian A et al (2008) Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis May 15 (Epub ahead of print)
24. GD Norata P Marchesi A Pirillo, et al. 2008 Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells Arterioscl Thromb Vasc Biol 28 925 931 18218986 10.1161/ATVBAHA.107.160606 1:CAS:528:DC%2BD1cXktlymu74%3D (Pubitemid 351544109)
25. W Dichtl L Nilsson I Goncalves, et al. 1999 Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells Circ Res 84 1085 1094 10325246 1:CAS:528:DyaK1MXjtFCjt70%3D
26. HJ Ting JP Stice UY Schaff, et al. 2007 Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha Circ Res 100 381 390 17234968 10.1161/01.RES.0000258023.76515.a3 1:CAS:528:DC%2BD2sXhsF2rsr4%3D (Pubitemid 46272410)
27. JP Lekakis CM Papamichael AT Cimponeriu, et al. 2000 Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis Am J Cardiol 85 949 952 10760332 10.1016/S0002-9149(99)00907-8 1:STN:280:DC%2BD3c3ntlKlsg%3D%3D (Pubitemid 30176131)
28. WJ Mack L LaBree C Liu, et al. 2000 Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography Atherosclerosis 150 371 379 10856529 10.1016/S0021-9150(99)00383-4 1:CAS:528:DC%2BD3cXktVSmsro%3D (Pubitemid 30336549)
29. A Bosutti G Grassi M Zanetti, et al. 2007 Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients Clin Exp Med 7 16 23 17380301 10.1007/s10238-007-0118-y 1:CAS:528:DC%2BD2sXjtlygtLk%3D (Pubitemid 46475004)
30. M Camozzi S Zacchigna M Rusnati, et al. 2005 Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo Arterioscler Thromb Vasc Biol 25 1837 1842 16020751 10.1161/01.ATV.0000177807.54959.7d 1:CAS:528:DC%2BD2MXos1ers7k%3D (Pubitemid 41243451)